Cheol-Hyung Lee, Yun Bin Lee, Minseok Albert Kim, Heejoon Jang, Hyunwoo Oh, Sun Woong Kim, Eun Ju Cho, Kyung-Hun Lee, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Tae-You Kim, Yoon Jun Kim
Clin Mol Hepatol 2020;26(3):328-339. Published online May 28, 2020
Background/Aims Several treatment options are currently available for patients with hepatocellular carcinoma (HCC) failing previous sorafenib treatment. We aimed to compare the effectiveness of regorafenib and nivolumab in these patients.
Methods Consecutive HCC patients who received regorafenib or nivolumab after failure of sorafenib treatment were included. Primary endpoint was overall survival (OS) and secondary endpoints were time to progression, tumor response rate, and adverse events. Inverse probability of treatment weighting (IPTW) using the propensity score was conducted to reduce treatment selection bias.
Results Among 150 study patients, 102 patients received regorafenib and 48 patients received nivolumab. Median OS was 6.9 (95% confidence interval [CI], 3.0–10.8) months for regorafenib and 5.9 (95% CI, 3.7–8.1) months for nivolumab (P=0.77 by log-rank test). In multivariable analysis, nivolumab was associated with prolonged OS (vs. regorafenib: adjusted hazard ratio [aHR], 0.54; 95% CI, 0.30–0.96; P=0.04). Time to progression was not significantly different between groups (nivolumab vs. regorafenib: aHR, 0.82; 95% CI, 0.51–1.30; P=0.48). HRs were maintained after IPTW. Objective response rates were 5.9% and 16.7% in patients treated with regorafenib and nivolumab, respectively (P=0.04).
Conclusions After sorafenib failure, the use of nivolumab may be associated with improved OS and better objective response rate as compared to using regorafenib.
Citations
Citations to this article as recorded by
Effectiveness of regorafenib in second-line therapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis Yunzhi Shen, Yu Bai Medicine.2025; 104(4): e41356. CrossRef
Efficacy and Safety of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Muhammad A.B. Naeem, Muhammad R. Paracha, Ahmad Noor, Muhammad H.A. Khalid, Hafiza K. Shahid, Maaz Khan, Moeaza R. Rizvi, Javeeria Arshad, Talha Abbas, Azeem Saeed, Hamza Ashraf, Minahil Ali, Mishal Asif, Aanusha Ghouri American Journal of Clinical Oncology.2025;[Epub] CrossRef
Impact of post‐progression survival in second‐line treatment with molecular target agents for unresectable hepatocellular carcinoma Kazuto Tajiri, Nozomu Muraishi, Aiko Murayama, Yuka Hayashi, Ichiro Yasuda Hepatology Research.2024; 54(4): 403. CrossRef
Approved immune checkpoint inhibitors in hepatocellular carcinoma: a large-scale meta-analysis and systematic review Ruyi Zhang, Fang Wang, Zhiyu You, Dongyang Deng, Jiangyan He, Wentao Yan, Jian Quan, Jing Wang, Shujuan Yan Journal of Cancer Research and Clinical Oncology.2024;[Epub] CrossRef
Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma Hong Jun Lee, Jae Seung Lee, Hyesung So, Ja Kyung Yoon, Jin-Young Choi, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim Yonsei Medical Journal.2024; 65(7): 371. CrossRef
Nivolumab as Second-Line Therapy Improves Survival in Patients with Unresectable Hepatocellular Carcinoma Faisal M. Sanai, Hassan O. Odah, Kanan Alshammari, Adnan Alzanbagi, Murooj Alsubhi, Hani Tamim, Ashwaq Alolayan, Ahmed Alshehri, Saleh A. Alqahtani Cancers.2024; 16(12): 2196. CrossRef
The interdisciplinary approach to investigate bona fide agent(s) in flavonoids or alkaloids in treating HCC Ki-Kwang Oh, Sang-Jun Yoon, Seol Hee Song, Jeong Ha Park, Jeong Su Kim, Min Ju Kim, Goo-Hyun Kwon, Dong Joon Kim, Ki-Tae Suk Artificial Cells, Nanomedicine, and Biotechnology.2024; 52(1): 500. CrossRef
Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis Yuwei Liu, Jiahui Pan, Fangbo Gao, Wentao Xu, Hongyu Li, Xingshun Qi Advances in Therapy.2023; 40(2): 521. CrossRef
Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis Bao-Wen Tian, Lun-Jie Yan, Zi-Niu Ding, Hui Liu, Cheng-Long Han, Guang-Xiao Meng, Jun-Shuai Xue, Zhao-Ru Dong, Yu-Chuan Yan, Jian-Guo Hong, Zhi-Qiang Chen, Dong-Xu Wang, Tao Li International Immunopharmacology.2023; 114: 109519. CrossRef
Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma Yuna Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Myung Ji Goh, Wonseok Kang, Seung Up Kim European Journal of Gastroenterology & Hepatology.2023; 35(2): 191. CrossRef
Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma Carmelo Laface, Girolamo Ranieri, Felicia Maria Maselli, Francesca Ambrogio, Caterina Foti, Michele Ammendola, Marigia Laterza, Gerardo Cazzato, Riccardo Memeo, Giovanni Mastrandrea, Marco Lioce, Palma Fedele Cancers.2023; 15(3): 654. CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Prognostic factors of nivolumab in advanced hepatocellular carcinoma: a systematic review and meta-analysis Ding XIONG, Kui ZHANG, Mingqing XU Panminerva Medica.2023;[Epub] CrossRef
Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook Yinjie Fan, Hang Xue, Huachuan Zheng Journal of Hepatocellular Carcinoma.2022; Volume 9: 233. CrossRef
Intrahepatic inflammatory IgA+PD-L1high monocytes in hepatocellular carcinoma development and immunotherapy Pil Soo Sung, Dong Jun Park, Pu Reun Roh, Kyoung Do Mun, Sung Woo Cho, Gil Won Lee, Eun Sun Jung, Sung Hak Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Jonghwan Choi, Jaegyoon Ahn, Seung Kew Yoon Journal for ImmunoTherapy of Cancer.2022; 10(5): e003618. CrossRef
Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma Kuo-Wei Huang, Pei-Chang Lee, Yee Chao, Chien-Wei Su, I-Cheng Lee, Keng-Hsin Lan, Chi-Jen Chu, Yi-Ping Hung, San-Chi Chen, Ming-Chih Hou, Yi-Hsiang Huang Therapeutic Advances in Medical Oncology.2022;[Epub] CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Clinical and Molecular Hepatology.2022; 28(4): 583. CrossRef
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
Korean Journal of Radiology.2022; 23(12): 1126. CrossRef
Blood-based biomarkers for immune-based therapy in advanced HCC: Promising but a long way to go Pil Soo Sung, Isaac Kise Lee, Pu Reun Roh, Min Woo Kang, Jaegyoon Ahn, Seung Kew Yoon Frontiers in Oncology.2022;[Epub] CrossRef
Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea Min Jin Lee, Sung Won Chang, Ji Hoon Kim, Young-Sun Lee, Sung Bum Cho, Yeon Seok Seo, Hyung Joon Yim, Sang Youn Hwang, Hyun Woong Lee, Young Chang, Jae Young Jang Investigational New Drugs.2021; 39(1): 260. CrossRef
Targeted treatment of alcoholic liver disease based on inflammatory signalling pathways Bingjian Wen, Chengcheng Zhang, Jingwen Zhou, Zhengyan Zhang, Qishi Che, Hua Cao, Yan Bai, Jiao Guo, Zhengquan Su Pharmacology & Therapeutics.2021; 222: 107752. CrossRef
Surgery versus external beam radiotherapy for hepatocellular carcinoma involving the inferior vena cava or right atrium: A systematic review and meta‐analysis Han Ah Lee, Sunmin Park, Yeon Seok Seo, Won Sup Yoon, In‐Soo Shin, Chai Hong Rim Journal of Hepato-Biliary-Pancreatic Sciences.2021; 28(12): 1031. CrossRef
The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis Shukang He, Weichao Jiang, Kai Fan, Xiaobei Wang Frontiers in Oncology.2021;[Epub] CrossRef
Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123. CrossRef
Evolving therapeutic strategies for advanced hepatocellular carcinoma Ammar Qureshi, Miguel Michel, Jaren Lerner, Constantin A. Dasanu Expert Opinion on Pharmacotherapy.2021; 22(18): 2495. CrossRef
Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1 Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho International Journal of Molecular Sciences.2021; 22(18): 10027. CrossRef
Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure Yuan-Hung Kuo, Yi-Hao Yen, Yen-Yang Chen, Kwong-Ming Kee, Chao-Hung Hung, Sheng-Nan Lu, Tsung-Hui Hu, Chien-Hung Chen, Jing-Houng Wang Frontiers in Oncology.2021;[Epub] CrossRef
Knockdown of Atg7 suppresses Tumorigenesis in a murine model of liver cancer Kyung Joo Cho, Sun Yeong Shin, Hyuk Moon, Beom Kyung Kim, Simon Weonsang Ro Translational Oncology.2021; 14(9): 101158. CrossRef
Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment Bo Hyun Kim, Joong-Won Park Journal of Liver Cancer.2021; 21(2): 124. CrossRef
Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review Kyoko Oura, Asahiro Morishita, Joji Tani, Tsutomu Masaki International Journal of Molecular Sciences.2021; 22(11): 5801. CrossRef
Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis Huilin Xu, Dedong Cao, Yongfa Zheng, Dingjie Zhou, Xin Chen, Jinju Lei, Wei Ge, Ximing Xu International Immunopharmacology.2021; 100: 108135. CrossRef
Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study Jaejun Lee, Ji-Won Han, Pil-Soo Sung, Soon-Kyu Lee, Hyun Yang, Hee-Chul Nam, Sun-Hong Yoo, Hae-Lim Lee, Hee-Yeon Kim, Sung-Won Lee, Jung-Hyun Kwon, Jeong-Won Jang, Chang-Wook Kim, Soon-Woo Nam, Jung-Suk Oh, Ho-Jong Chun, Si-Hyun Bae, Jong-Young Choi, Seun Journal of Clinical Medicine.2021; 10(18): 4045. CrossRef
Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma Sojung Han, Do Young Kim Clinical and Molecular Hepatology.2020; 26(3): 305. CrossRef
Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma Mohamed A. Abd El Aziz, Antonio Facciorusso, Tarek Nayfeh, Samer Saadi, Mohamed Elnaggar, Christian Cotsoglou, Rodolfo Sacco Vaccines.2020; 8(4): 616. CrossRef
First
Prev
